AI-powered Lunit INSIGHT CXR and Lunit INSIGHT MMG to enhance lung and breast cancer detection in Taiwan and Singapore
SEOUL, South Korea, March 11, 2024 /PRNewswire/ — Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced two supply contracts that mark its strategic expansion into the East and Southeast Asian region. Lunit will supply its Lunit INSIGHT CXR for chest abnormality detection and Lunit INSIGHT MMG for mammography analysis to the Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore, respectively.
Chung Shan Medical University to Pioneer AI in Lung Cancer Detection
Under the newly inked supply contract, Lunit will collaborate with the prestigious Chung Shan Medical University (CSMU), Taiwan’s leading medical university. This collaboration holds the potential to revolutionize Taiwan’s national lung cancer screening program.
Compared to Taiwan’s current screening program, which relies on low‐dose computed tomography (LDCT) for …